Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis

Table 5

Drug resistance of E. coli (ESBL +/-) in mild and severe patients.

	ESBLs + (n=34)					ESBLs - (n=8)
	Mild		Severe		P	Mild		Severe		P
	n=18	%	n=16	%		n=1	%	n=7	%
Ampicillin	14	77.78	15	93.75	0.1893	0	0	4	57.14	NA
Ampicillin-sulbactam	12	66.67	13	81.25	0.3360	0	0	2	28.57	NA
Aztreonam	18	100	11	68.75	0.0102	0	0	1	14.29	NA
Cefazolin	16	88.89	16	100	0.1693	0	0	1	14.29	NA
Ceftriaxone	16	88.89	16	100	0.1693	0	0	1	14.29	NA
Ceftazidime	6	33.33	8	50	0.3243	0	0	1	14.29	NA
Cefotetan	0	0	0	0	NA	0	0	0	0	NA
Cefepime	9	50	9	56.25	0.7155	0	0	0	0	NA
Piperacillin/tazobactam sodium	2	11.11	0	0	NA	0	0	0	0	NA
Imipenem	0	0	0	0	NA	0	0	0	0	NA
Ertapenem	0	0	0	0	NA	0	0	0	0	NA
Ciprofloxacin	18	100	15	93.75	0.2817	1	100	3	42.86	NA
Levofloxacin	18	100	12	75	0.0239	1	100	3	42.86	NA
Amikacin	3	16.67	3	18.75	0.8736	0	0	0	0	NA
Gentamicin	12	66.67	7	43.75	0.1792	0	0	3	42.86	NA
Tobramycin	8	44.44	6	37.5	0.6813	0	0	2	28.57	NA
Trimethoprim/sulfamethoxazole	11	61.11	10	62.5	NA	1	100	4	57.14	NA